The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

ASH Oral and Poster Presentations: 2022

Collaborative Oral Presentations:

158 Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma - Noopur Raje, MD1, Nizar Jacques Bahlis, MD2, Caitlin Costello, MD3, Bhagirathbhai Dholaria, MBBS4, Melhem Solh, MD5, Moshe Yair Levy, MD6, Michael H Tomasson, MD7*, Michael A. Damore, PhD8*, Sibo Jiang, PhD9*, Cynthia Basu, PhD10*, Athanasia Skoura, PhD11*, Edward M Chan, MD12*, Suzanne Trudel13, Andrzej Jakubowiak, MD, PhD14*, Michael P Chu, MD15*, Cristina J. Gasparetto, MD16, Andrew P. Dalovisio, MD17, Michael Sebag, MD, PhD18 and Alexander M Lesokhin, MD19

655 Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study - Jeremy S. Abramson, MD1, Scott R. Solomon, MD2, Jon E. Arnason, MD3, Patrick B. Johnston, MD, PhD4, Bertram Glass, MD5*, Veronika Bachanova, MD, PhD6, Sami Ibrahimi, MD7, Stephan Mielke, MD8, Pim Mutsaers, MD9*, Francisco Hernandez-Ilizaliturri, MD10, Koji Izutsu11*, Franck Morschhauser, MD, PhD12*, Matthew A. Lunning, DO, FACP13, Alessandro Crotta, MD14*, Sandrine Montheard, MS14*, Alessandro Previtali, MSc14* and Manali Kamdar, MD, MBBS15*

Poster Presentations:

2070 Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus - Melhem Solh, MD1, Scott R. Solomon, MD1, Xu Zhang, PhD2*, Lawrence E. Morris Jr., MD1*, Lizamarie Bachier-Rodriguez, MD1*, H. Kent Holland, MD1 and Asad Bashey, MD, PhD1

2120 Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype - Scott R. Solomon, MD1, Lizamarie Bachier-Rodriguez, MD1*, Xu Zhang, PhD2*, Michael T Aubrey3*, Christina L Roark3*, Lawrence E. Morris Jr., MD1*, H. Kent Holland, MD1, Asad Bashey, MD, PhD1 and Melhem Solh, MD1

3368 Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center - Asad Bashey, MD, PhD1, Xu Zhang, PhD2*, Scott R. Solomon, MD1, Lizamarie Bachier-Rodriguez, MD1*, H. Kent Holland, MD1, Lawrence E. Morris Jr., MD1* and Melhem Solh, MD1

3404 Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide - Scott R. Solomon, MD1, Lizamarie Bachier-Rodriguez, MD1*, Xu Zhang, PhD2*, H. Kent Holland, MD1, Lawrence E. Morris Jr., MD1*, Asad Bashey, MD, PhD1 and Melhem Solh, MD1

3444 HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY) - Melhem Solh, MD1, Michael T Aubrey2*, Xu Zhang, PhD3*, Asad Bashey, MD, PhD1, Brian M Freed2*, Christina L Roark2*, Lizamarie Bachier-Rodriguez, MD1*, Lawrence E. Morris Jr., MD1*, H. Kent Holland, MD1 and Scott R. Solomon, MD1

4763 TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia - Scott R. Solomon, MD1, Lizamarie Bachier-Rodriguez, MD1*, Xu Zhang, PhD2*, Asad Bashey, MD, PhD1, Lawrence E. Morris Jr., MD1*, H. Kent Holland, MD1 and Melhem Solh, MD1

4944 Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program - Asad Bashey, MD, PhD1, Xu Zhang, PhD2*, Melhem Solh, MD1, H. Kent Holland, MD1, Lawrence E. Morris Jr., MD1*, Lizamarie Bachier-Rodriguez, MD1* and Scott R. Solomon, MD1

2005 Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma - Caron A. Jacobson, MD1, Tilanthi Jayawardena, PhD2*, Lou Yu, MS3*, Jason Hallman2*, Robert Schmittling2*, Erin Cuneo2*, Ian Belle, PhD2*, Gavin Sampey, PhD2*, Danica Cabral2*, Ashleigh Derrick2*, Josie Tueller2*, Koen Van Besien, MD, PhD4,5, Scott R. Solomon, MD6,7, Adam J. Olszewski, MD8,9, Joseph E. Maakaron, MD10,11, Ran Reshef, MD, MSc12,13, Anthony S. Stein, MD14, Abhinav Deol, MD15, Nitin Jain, MD16, Alan F. List, MD2 and Bijal D. Shah, MD17,18

2771 CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts - Camille Abboud Sr., MD1, Jan Maciej Zaucha, MD2*, Scott R. Solomon, MD3, Terrence Bradley, MD4, Elie Mouhayar, MD5*, Noemi Angelosanto, MD6, Hendrik Nogai, MD6*, Renata Dudziak, MD7*, Tomasz Rzymski, PhD6*, Peter Littlewood, BSc8*, Krzysztof Brzózka, PhD6*, Axel Glasmacher, MD9, Gautam Borthakur, MD10, Howard A. Burris Sr., MD11 and Ewa Lech Marańda, MD, PhD12*

2960 Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial - Juan Pablo Alderuccio, MD1, Russ A Kuker, MD2*, Isildinha M Reis, PhD3*, Muthiah Nachiappan, MD4*, Brad S. Kahl, MD5, Mehdi Hamadani, MD6, Weiyun Z. Ai, MD, PhD7, John Radford, MD, FRCPath, FMedSci8*, Melhem Solh, MD9, Kirit M. Ardeshna10, Brian T. Hess, MD11, Matthew A. Lunning, DO, FACP12, Pier Luigi Zinzani, MD, PhD13, Anastasios Stathis, MD14*, Carmelo Carlo-Stella, MD, PhD15, Eric Yu, PhD16*, Paolo F Caimi, MD17,18*, Deukwoo Kwon, PhD19*, Izidore S. Lossos, MD20, Fei Yang, PhD21* and Craig H. Moskowitz, MD22

3442 Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers - Tania Jain, MD1, Hua-Ling Tsai, ScM2*, Hany Elmariah, MD, MS3, Pankit Vachhani, MD4*, Theodoros Karantanos, MD, PhD5, Sarah A Wall, MD, MPH6, Lukasz P. Gondek, MD, PhD7, Asad Bashey, MD, PhD8, Alla Keyzner, MD9, Michael R. Grunwald, MD10, Sameem Abedin, MD11, Kalyan VG Nadiminti, MD12, Madiha Iqbal, MD13, Aaron T. Gerds, MD, MS14, Auro Viswabandya, MD, DM15*, Shannon R McCurdy, MD16*, MHD Monzr M. Al Malki, MD17, Ravi Varadhan, PhD2*, Haris Ali, MD18, Vikas Gupta, MD, FRCP, FRCPath19, Richard J. Jones, MD1 and Salman Otoukesh, MD20*

4252 A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses - Tamer Othman, MD1*, Christopher Ruel2*, Paul Frankel, PhD2*, Alexander A. Merleev, PhD1*, Guillaume Luxardi, PhD1*, Emanual Maverakis, MD1*, Mehrdad Abedi, MD1, Raghuveer Ranganathan, MD3*, Jasmine Zain, MD2, Lihua E Budde, MD, PhD2, Matthew Mei, MD2, Aaron S Rosenberg, MD1, Rasmus T Hoeg, MD1*, Caitlin Costello, MD4, Francine M. Foss, MD5, Basem M. William, MRCP, MD6, H. Kent Holland, MD7, Miguel Villalona-Calero, MD2*, Elad Sharon, MD, MPH8* and Joseph M Tuscano, MD1